^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YB-200

    i
    Other names: YB-200
    Associations

    News

    Trials
    Company:
    Ymmunobio
    Drug class:
    CEACAM1 agonist, CEACAM5 agonist
    Associations

    News

    Trials
    over3years
    Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment (SITC 2022)
    Ethics Approval This animal study has been approved by the Ethics Committee for Animal Experimentation and is registered by the regional board Freiburg, Germany. Mice were handled according to the German animal welfare law and the GV-SOLAS guidelines.
    Clinical
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    YB-200